Recent Updates
Recently added Catalysts
PRAX Positive Sentiment

Praxis Precision Medicines to Present at H.C. Wainwright 25th Annual Global Investment Conference

Thursday, September 7, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Praxis Precision Medicines, Inc. announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference, scheduled for September 12, 2023. The management will engage in a fireside chat to discuss the company's progress and vision. The event aims to provide insights into the company's innovative therapies for CNS disorders, and will be accessible through a live webcast.
Price reaction · baseline $20.55 (2023-09-06 close) · hit after-hours · clean, no other PRAX news in the window
day 0 close · peak
+5.1%
day 1
+1.5%
day 3
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Praxis Precision Medicines is actively engaging with investors at a major conference.
  • The participation in the H.C. Wainwright conference highlights the company's commitment to transparency and communication.
  • The company's focus on CNS disorders shows potential for significant therapeutic advancements.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+61%
120-day peak, hindsight
Typical move
23.7%
average across 12 past catalysts
Cash runway
~53 mo
Minimal dilution risk
Lead asset
vormatrogine
Phase 3 · Epilepsy, Tonic-Clonic

Full Press Release Details

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023 at 12 p.m. EDT.
The event will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 30 days following the event.

Frequently Asked Questions

When will Praxis participate in the investment conference?

Praxis will partake in the conference on September 12, 2023, at 12 p.m. EDT.

Where can I watch the live webcast of the event?

The live webcast will be available on the Investors + Media section of Praxis' website.

How long will the webcast replay be available?

The replay of the webcast will be accessible for 30 days after the event.

What is Praxis Precision Medicines focused on?

Praxis is focused on developing therapies for CNS disorders using genetic insights.

ShareAdd on Google
Tags: PRAX Viatris Investor Conferences Healthcare CNS disorders H.C. Wainwright biopharmaceutical investment conference
Last updated: Sep 7, 2023

Biotech snapshot

Cash runway
$1374M liquidity · $26M/mo burn
~53 mo
Minimal dilution risk
Lead asset
vormatroginePhase 3
Epilepsy, Tonic-Clonic →

Catalyst track record

+61%
best trade around PRAX's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for PRAX.

See every catalyst's timing & PoA →